Patent application number | Description | Published |
20090075878 | Methods for Generating and Screening Fusion Protein Libraries and Uses Thereof - The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins. | 03-19-2009 |
20090305972 | NOVEL CANCER-ASSOCIATED ANTIGEN - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immuno-conjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 12-10-2009 |
20100145023 | Optimized Nucleotide Sequences of VB6-845 For Expression of Recombinant Proteins - An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the V | 06-10-2010 |
20100215670 | Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers - Novel conjugates are disclosed which comprise (a) a ligand that binds to a surface molecule on a target cell, such as a cancer cell; (b) an effector molecule that is to be delivered into the cell, such as a toxin; and (c) a linker sequence that couples the ligand and the effector molecule wherein the linker comprises at least one protease cleavage site corresponding to a protease found in the intracellular trafficking pathway of the effector molecule; wherein the cleavage of the linker by the protease uncouples the effector molecule from the ligand. | 08-26-2010 |
20100254982 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof. | 10-07-2010 |
20100267086 | Optimized Nucleic Acid Sequences For The Expression of VB4-845 - An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the V | 10-21-2010 |
20100303814 | Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof. | 12-02-2010 |
20100322919 | Antibodies Against a Cancer-Associated Epitope of Variant NFKBIB and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof. | 12-23-2010 |
20120058106 | NOVEL CANCER-ASSOCIATED ANTIGEN - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 03-08-2012 |
20120128723 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof. | 05-24-2012 |
20130039931 | Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens, and uses thereof. | 02-14-2013 |
20130217865 | Tumor Specific Antibody - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention. | 08-22-2013 |
20130243799 | NOVEL CANCER-ASSOCIATED ANTIGEN - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 09-19-2013 |
20130344076 | ANTIBODY CONJUGATES AGAINST VARIANT NFKBIB AND USES THEREOF - The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof. | 12-26-2013 |
20150018526 | Cytotoxins comprising modified bouganin toxin for the treatment of cancer - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 01-15-2015 |